Hostname: page-component-78c5997874-94fs2 Total loading time: 0 Render date: 2024-11-02T21:23:57.425Z Has data issue: false hasContentIssue false
  • English
  • Français

From Clinical Research to Clinical Practice: A 4-Year Review of Ziprasidone

Published online by Cambridge University Press:  07 November 2014

Prakash S. Masand ,
Charles B. Nemeroff ,
John W. Newcomer ,
Jeffrey A. Lieberman ,
Alan F. Schatzberg ,
Peter J. Weiden ,
Clinton D. Kilts ,
Philip D. Harvey  and
David G. Daniel
Get access Rights & Permissions [Opens in a new window]

Abstract

Ziprasidone is a second-generation antipsychotic that received Food and Drug Administration approval in February 2001. It has a unique receptor profile that includes high-affinity antagonist activity at dopamine D2 receptors, inverse agonist activity at serotonin (5-HT)2A receptors, agonist activity at 5-HT1A receptors, and a relatively high affinity for the serotonin and norepinephrine transporters. The 5-HT1A affinity, together with the inhibitory effect on monoamine reuptake, may underlie the hypothesized beneficial effects on comorbid affective and cognitive abnormalities in schizophrenia and schizoaffective disorder. The short-term efficacy of ziprasidone for core positive symptoms of schizophrenia appears to be comparable to other conventional and atypical antipsychotics. The short-term efficacy of ziprasidone in acute mania has been established based on two 3-week, double-blind, placebo-controlled trials. Open-label treatment for up to 52 weeks confirms the sustained efficacy and safety of ziprasidone in bipolar disorder. Maintenance studies in schizophrenia and schizoaffective disorder indicate that long-term ziprasidone therapy is effective in preventing relapse, while maintaining cognitive and psychosocial benefits. The safety database suggests that the overall cardiovascular and cerebrovascular risk associated with ziprasidone is lower than with other atypicals, with notably lower risk of drug-related increases in weight, glucose, or lipids. The data also suggest a modestly increased risk of QTc prolongation that is not dose related or linked to torsades de pointes. Switching to ziprasidone from other atypicals appears to improve both clinical symptoms and metabolic parameters, though more studies are needed to fully characterize these benefits. This monograph summarizes the efficacy, tolerability, and safety of oral ziprasidone in the treatment of schizophrenia, schizoaffective disorder, and bipolar mania.

Type
Research Articles
Information
CNS Spectrums , Volume 10 , Issue S17 , November 2005 , pp. 1 - 20
Copyright
Copyright © Cambridge University Press 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Daniel, DG, Potkin, SG, Reeves, KR, Swift, RH, Harrigan, ER. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Beri). 2001;155:128–134.CrossRefGoogle ScholarPubMed
2.Lesem, MD, Zajecka, JM, Swift, RH, Reeves, KR, Harrigan, ER. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry. 2001;62:12–18.CrossRefGoogle ScholarPubMed
3.Brook, S, Walden, J, Benattia, I, Siu, CO, Romano, SJ. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. Psychopharmacology (Beri). 2005;178:514–523.CrossRefGoogle Scholar
4.Richelson, E, Souder, T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000;68:29–39.CrossRefGoogle ScholarPubMed
5.Shapiro, DA, Renock, S, Arrington, E, et al. Aripiprazole, a novel atypical anti-psychotic drug with a unique and robust pharmacology. Neuropsycbopharmacol. 2003;28:1400–1411.CrossRefGoogle Scholar
6.Weiner, DM, Meitzer, HY, Veinbergs, I, et al. The role of Ml muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacol. 2004;177:207–216.CrossRefGoogle ScholarPubMed
7.Schmidt, AW, Lebel, LA, Howard, HR Jr, Zorn, SH. Ziprasidone: a novel anti-psychotic agent with a unique human receptor binding profile. Eur J Pharmacol. 2001;425:197–201.CrossRefGoogle ScholarPubMed
8.DeLeon, A, Patel, NC, Crismon, ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther. 2004;26:649–666.CrossRefGoogle ScholarPubMed
9.Stahl, SM, Shayegan, DK. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64(suppl 19):6–12.Google ScholarPubMed
10.Kroeze, WK, Hufeisen, SJ, Popadak, BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsycbopharmacol. 2003;28:519–526.CrossRefGoogle ScholarPubMed
11.Duman, RS. Depression: a case of neuronal life and death? Biol Psychiatry. 2004;56:140–145.CrossRefGoogle ScholarPubMed
12.Thome, J, Foley, P, Riederer, P. Neurotrophic factors and the maldevelopmen-tal hypothesis of schizophrenic psychoses. Review article. J Neural Tramm. 1998;105:85–100.CrossRefGoogle ScholarPubMed
13.Arango, C, Kirkpatrick, B, Koenig, J. At issue: stress, hippocampal neuronal turnover, and neuropsychiatrie disorders. Schizophr Bull. 2001;27:477–480.CrossRefGoogle Scholar
14.Garver, DL, Holcomb, JA, Christensen, JD. Cerebral cortical gray expansion assoeiated with two second-generation antipsychotics. Biol Psychiatry. 2005;58:62–66.CrossRefGoogle Scholar
15.Prakash, C, Kamel, A, Cui, D, Whalen, RD, Miceli, JJ, Tweedie, D. Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Br J Clin Pharmacol. 2000;49(suppl 1):35S–42S.CrossRefGoogle ScholarPubMed
16.Beedham, C, Miceli, JJ, Obach, RS. Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J Clin Psychopharmacol. 2003;23:229–232.CrossRefGoogle ScholarPubMed
17.Miceli, JJ, Wilner, KD, Hansen, RA. Single and multiple dose pharmacokinetics of ziprasidone under non-fasting conditions in healthymale volunteers. Br J Clin Pharmacol. 2000;49(suppl 1):5S–13S.CrossRefGoogle Scholar
18.Hamelin, BA, Allard, S, Laplante, L, et al. The effect of timing of a standard meal on rhe pharmacokinetics and pharmacodynamics of the novel atypical antipsy-chotic agent ziprasidone. Pharmacotherapy. 1998;18:9–15.CrossRefGoogle Scholar
19.Miceli, JJ, Smith, M, Robarge, L, Morse, T, Laurent, A. The effects of ketoconazole on ziprasidone pharmacokinetics: a placebo-controlled crossover study in healthy volunteers. Br J Clin Pharmacol. 2000;49(suppl 1):S71–S76.CrossRefGoogle ScholarPubMed
20.Miceli, JJ, Anziano, RJ, Robarge, L, Hansen, RA, Laurent, A. The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers. Br J Clin Pharmacol. 2000; 49:(suppl 1):S65–S70.CrossRefGoogle ScholarPubMed
21.Apseloff, G, Mullet, D, Wilner, KD, et al. The effects of ziprasidone on steady-state lithium levels and renal clearance of lithium. Br J Clin Pharmacol. 2000;49(suppl 1):S61–S64.CrossRefGoogle ScholarPubMed
22.Obach, RS, Huynh, P, Allen, MC, Beedham, C. Human liver aldehyde oxidase: inhibition by 239 drugs. J Clin Pharmacol. 2004;44:7–19.CrossRefGoogle ScholarPubMed
23. Geodon (package insert), New York, NY: Pfizer, Inc.; December 2003.Google Scholar
24.Murray, S, Mandel, FS, Loebel, A. Optimal initial dosing of ziprasidone: clinical trial data. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.Google Scholar
25.Mamo, D, Kapur, S, Shammi, CM, et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry. 2004;161:818–825.CrossRefGoogle ScholarPubMed
26.Weiden, PJ, Iqbal, N, Mendelowitz, AJ, Tandon, R, Zimbroff, DL, Ross, R. Best clinical practice with ziprasidone: Update after one year of experience. J Psych Pract. 2002;8:81–97.Google ScholarPubMed
27.Joyce, AT, Harrison, DJ, Ollendorf, DA. Effect of ziprasidone initial dosing on discontinuation. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.CrossRefGoogle Scholar
28.Pozzi, L, Acconcia, S, Ceglia, I, et al. Stimulation of 5-hydroxytryptamine (5-HT(2Q) receptors in the ventrotegmental area inhibits stress-induced but not basal dopamine release in the rat prefrontal cortex. J Neurochem. 2002;82:93–100.CrossRefGoogle Scholar
29.Bonaccorso, S, Meitzer, HY, Li, Z, et al. SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsycbopharmacol. 2002;27:430–441.CrossRefGoogle Scholar
30.Harrigan, EP, Miceli, JJ, Anziano, R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol. 2004;24:62–69.CrossRefGoogle ScholarPubMed
31.Daniel, DG. Tolerability of ziprasidone: an expanding perspective. J Clin Psychiatry. 2003;64(suppl 19):40–49.Google ScholarPubMed
32.Deutschman, DA, Deutschman, DH. High-dose ziprasidone: Efficacy and toler-ability in clinical practice. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.Google Scholar
33.Miceli, JJ, Murray, S, Sallee, FR, Tensfeldt, TG, Versavel, M. Phamacokinetic and pharmacodynamic QTc profile of oral ziprasidone in pediatric and adult subjects following single-dose administration. Poster presenred at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.Google Scholar
34.Lindenmayer, JP, Czobor, P, Volavka, J, et al. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia. J Clin Psychiatry. 2004;65:551–556.CrossRefGoogle ScholarPubMed
35.Lindenmayer, JP, Bernstein-Hyman, R, Grochowski, S, Bark, N. Psychopathology ot schizophrenia: initial validation of a 5-factor model. Psycbopatbology. 1990;28;22–31.CrossRefGoogle Scholar
36.Potkin, SG, Anand, R, Alphs, L, Fleming, K. Neurocognitive performance does not correlate with suicidality in schizophrenic and schizoaffective patients at risk fur suicide. Schizophr Res. 2003;59:59–66.CrossRefGoogle ScholarPubMed
37.Heydebrand, G, Weiser, M, Rabinowitz, J, Hoff, AL, DeLisi, LE, Csernansky, JG. Correlates of cognitive deficits in first episode schizophrenia. Schizophr Res. 2004;68:1–9.CrossRefGoogle ScholarPubMed
38.Goff, DC, Posever, T, Herz, L, et al. An exploratory haloperidol-conrrolled dosefinding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol. 1998;18:296–304.CrossRefGoogle ScholarPubMed
39.Addington, D, Pantelis, C, Dineen, M. Ziprasidone vs risperidone in schizophrenia: 52 weeks' comparative data. Poster presented at: the 156th Annual Meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, CA.Google Scholar
40.Simpson, GM, Glick, ID, Weiden, PJ, Romano, SJ, Siu, CO. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability ot ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161:1837–1847.CrossRefGoogle ScholarPubMed
41.Geddes, J, Freemantle, N, Hatrison, P, Bebbington, P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Br Med J. 2000;321:1371–1376.CrossRefGoogle ScholarPubMed
42.Bagnali, AM, Joncs, L, Ginnclly, L, et al. A systematic review of atypical antipsy-chotic drugs in schizophrenia. Health Tech Assess. 2003;7(13):1–193.Google Scholar
43.Lieberman, JA, Stroup, TS, McEvoy, JP. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209–1223.CrossRefGoogle ScholarPubMed
44.Harrison, DJ, Joyce, AT, Olldendorf, DA. Impact of atypical agents on outcomes of care in schizophrenia. Poster presented at: 158th Annual Meeting of the American Psychiatric Association; May 21-26, 2005; Atlanta, GA.Google Scholar
45.Siris, SG. Depression in schizophrenia: perspective in the era of “Atypical” antipsychotic agents. Am J Psychiatry. 2000;157:1379–1389.CrossRefGoogle ScholarPubMed
46.Keck, PE Jr, Reeves, KR, Harrigan, EP, et al. Ziprasidone in the short-term treat-mem of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies. J Clin Psychopharmacol. 2001;21:27–35.CrossRefGoogle ScholarPubMed
47.Daniel, DG, Zimbroff, DL, Potkin, SG, Reeves, KR, Harrigan, EP, Lakshminarayanan, M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsycbopharmacol. 1999;20:491–505.CrossRefGoogle ScholarPubMed
48.Keck, P Jr, Butfenstein, A, Ferguson, J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Beri). 1998;140:173–184.CrossRefGoogle ScholarPubMed
49.Kane, JM. Oral ziprasidone in the treatment of schizophrenia: a review of shortterm trials. J Clin Psychiatry. 2003;64(suppl 19):19–25.Google ScholarPubMed
50.Elvevag, B, Goldberg, TE. Cognitive impairmenr in schizophrenia is the core of the disorder. Crtt Rev Neurobiol. 2000;14:1–21.Google ScholarPubMed
51.Gleen, MF, Nuechterlein, KH, Gold, JM, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the N1MH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry. 2004;56:301–307.Google Scholar
52.Davalos, DB, Compagnon, N, Heinlein, S, Ross, RG. Neuropsychological deficits in children associated with increased familial risk for schizophrenia. Schizophr Res. 2004;67:123–130.CrossRefGoogle ScholarPubMed
53.Palmer, BW, Heaton, RK, Paulsen, JS, et al. Is it possible to be schizophrenic yet neuropsychologically normal? Neuropsychology. 1997;11:437–446.CrossRefGoogle ScholarPubMed
54.Harvey, PD, Keefe, RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry. 2001;158:176–184.CrossRefGoogle ScholarPubMed
55.Heinrichs, RW, Zakzanis, KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998;12:426–445.CrossRefGoogle ScholarPubMed
56.Harvey, PD, Meitzer, H, Simpson, GM, et al. Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophr Res. 2004;66:101–113.CrossRefGoogle ScholarPubMed
57.Harvey, PD, Siu, CO, Romano, S. Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapili: in acutely ill inpatients with schizophrenia or schizoaffective disorder. Psychopharmacol 2004;172:324–332.CrossRefGoogle ScholarPubMed
58.Harvey, PD, Bowie, CR, Loebel, A. Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a 6-month, randomized, double-blind comparison of ziprasidone vs. olanzapine. J Neuropsych Clin Neurosci. In press.Google Scholar
59.Hegarty, JD, Baldessarini, RJ, Tohen, M. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry. 1994;151:1409–1416.Google ScholarPubMed
60.Dickerson, FB, Ringel, N, Parents, F. Predictors of residential independence among outpatients with schizophrenia. Psychiatr Serv. 1999;5:515–519.CrossRefGoogle Scholar
61.Macdonald, EM, Hayes, RL, Baglioni, AJ Jr. The quantity and quality of the social networks of young people with early psychosis compared with closely matched controls. Schizophr Res. 2000;46:25–30.CrossRefGoogle ScholarPubMed
62.Haukka, J, Suvisaari, J, Lonnqvist, J. Fertility of patients with schizophrenia, their siblings, and the general population: a cohort study from 1950 to 1959 in Finland. Am J Psychiatry. 2003;160:460–463.CrossRefGoogle ScholarPubMed
63.Purnine, DM, Carey, KB, Maistro, SM, Karey, MP. Assessing positive and negative symptoms in patients with schizophrenia and mood disorders. J Nerv Ment Dis. 2000;188:653–661.CrossRefGoogle Scholar
64.Loebel, A, Siu, C, Romano, S. Improvement in prosocial functioning after a switch to ziprasidone treatment. CNS Spectr. 2004;9:357–364.CrossRefGoogle ScholarPubMed
65. The World Health Report: 2001. Mental Health: New Understanding, New Hope. Available at: hrtp://www.who.int/whr\2001/en/. Accessed October 4, 2005Google Scholar
66.Arato, M, O'Connor, R, Meitzer, HY. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol. 2002;17:207–215.CrossRefGoogle Scholar
67.Schooler, NR. Maintaining symptom control: review of ziprasidone longterm efficacy data. J Clin Psychiatry. 2003;64(suppl 19):26–32.Google ScholarPubMed
68.Simpson, GM, Weiden, PJ, Loebel, A, Warrington, L, Yang, R. Ziprasidone: long-term post-switch efficacy in schizophrenia. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.Google Scholar
69.O'Connor, R, Schooler, NR. Penulrimate observation carried forward (POCF): a new approach to analysis of long-term symptom change in chronic relapsing conditions [letter]. Schizophr Res. 2003;60:319–320.CrossRefGoogle ScholarPubMed
70.Weiden, PJ, Simpson, GM, Potkin, SG, O'Sullivan, RL. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry. 2003;64:580–588.CrossRefGoogle ScholarPubMed
71.Weiden, PJ, Daniel, DG, Simpson, GM, Romano, SJ. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol. 2003;23:1–6.CrossRefGoogle ScholarPubMed
72.Contey, RR, Buchanan, RW. Evaluation of treatment-resistant schizophrenia. Schizophr Bull. 1997;23:663–674.Google Scholar
73.Basu, A. Cost-effectiveness analysis of pharmacological treatments in schizophrenia: critical review of results and methodological issues. Schizophr Res. 2004;71:445–462.CrossRefGoogle ScholarPubMed
74.Essock, SM, Hargreaves, WA, Covell, NH. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharm Bull. 1996;32:683–697.Google ScholarPubMed
75.Rosenheck, R, Cramer, J, Xu, W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med. 1997;337:809–815.CrossRefGoogle ScholarPubMed
76.Tuunainen, A, Wahlbeck, K, Gilbody, S. Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials. Schizophr Res. 2002;56:1–10.CrossRefGoogle ScholarPubMed
77.Moncrieff, J. Clozapine, v. conventional antipsychotic drugs for treatment-resistant schizophrenia: a re-examination. Br J Psychiatry. 2003;183:161–166.CrossRefGoogle ScholarPubMed
78.Kane, J, Khanna, S, Giller, E, Rajadhyaksha, S, Loebel, A, Siu, E. Efficacy and tolerability of ziprasidone in treatment-resistant schizophrenia. Int Clin Psychopharmacol. In press.Google Scholar
79.Rothschild, AJ. Management of psychotic, treatment-resistant depression. Psychiatr Clin North Am. 1996;19:237–252.CrossRefGoogle ScholarPubMed
80.Kessler, RC, McGonagle, KA, Zhao, S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comotbidity Survey. Arch Gen Psychiatry. 1994;51:8–19.CrossRefGoogle ScholarPubMed
81.Rush, AJ, Thase, ME, Dube, S. Research issues in the study of difficult-to-treat depression. Biol Psychiatry. 2003;53:743–753.CrossRefGoogle Scholar
82.Kohler, CG, Lallart, EA. Postpsychotic depression in schizophrenia patients. Curr Psychiatry Rep. 2002;4:273–278.CrossRefGoogle ScholarPubMed
83.Tohen, M, Goldberg, JF, Gonzalez-Pinto Arrillaga, AM, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry. 2003;60:1218–1226.CrossRefGoogle ScholarPubMed
84.Tohen, M, Zhang, F, Keck, PE, et al. Olanzapine versus haloperidol in schizoaf-fective disorder, bipolar type. J Affect Disord. 2001;67:133–140.CrossRefGoogle ScholarPubMed
85.Tohen, M, Jacobs, TG, Grundy, SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2000;57:841–849.CrossRefGoogle Scholar
86.Tohen, M, Chengappa, KN, Suppes, T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry. 2002;59:62–69.CrossRefGoogle ScholarPubMed
87.DelBello, MP, Schwiers, ML, Rosenberg, HL, Strakowski, SM. A double-blind, randomized, placebo-conrrolled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry. 2002;41:1216–1223.CrossRefGoogle ScholarPubMed
88.Casey, DE, Daniel, DG, Wassef, AA, Tracy, KA, Wozniak, P, Sommerville, KW. Effect of divalproex combined with olanzapine ot risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology. 2003;28:182–192.CrossRefGoogle Scholar
89.Brambilla, P, Barale, F, Soares, JC. Atypical antipsychotics and mood stabilization in bipolar disorder. Psychopharmacol. 2003;166:315–332.CrossRefGoogle ScholarPubMed
90.Hirschfeld, RM, Keck, PE Jr, Kramer, M, et al. Rapid anrimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry. 2004;161:1057–1065.CrossRefGoogle ScholarPubMed
91.Potkin, SG, Keck, P, Giller, E, Ice, K, Warrington, L, Mandel, FS. Ziprasidone in bipolar mania: efficacy across patient subgroups. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.Google Scholar
92.Keck, PE, Potkin, S, Watrington, L, Loebel, A, Giller, E, Batzar, E. Efficacy and safety of ziprasidone in bipolar disorder: short- and long-term data. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.Google Scholar
93.Papakostas, Gl, Petersen, TJ, Neirenberg, AA, et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSR I-res istant major depressive disorder. J Clin Psychiatry. 2004;65:217–221.CrossRefGoogle Scholar
94.Joukamaa, M, Heliovaara, M, Knekt, P, Aromaa, A, Raitasalo, R, Lehtinen, V. Mental disorders and cause-specific mortality. Br J Psychiatry. 2001;179:498–502.CrossRefGoogle ScholarPubMed
95.Harris, EC, Barraclough, B. Excess mortality of mental disorder. Br J Psychiatry. 1998;173:11–53.CrossRefGoogle ScholarPubMed
96.Osby, U, Brandt, L, Correia, N, Ekbom, A, Sparen, P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58:844–850.CrossRefGoogle ScholarPubMed
97.Jamison, KR. Suicide and bipolar disorder. J Clin Psychiatry. 2000;61(suppl 9):47–51.Google ScholarPubMed
98.Davidson, S, Judd, F, Jolley, D, Hocking, B, Thompson, S, Hyland, B. Cardiovascular risk factors for people with mental illness. Aust N Z J Psychiatry. 2001;35:196–202.CrossRefGoogle ScholarPubMed
99.Casey, DE, Haupt, DW, Newcomer, JW, et al. Antipsychotic-induced weight gain and metabolic abnormalities: Implications for increased mortality in patients with schizophrenia. J Clin Psychiatry. 2004;65(suppl 7):4–18.Google ScholarPubMed
100.Zhang, ZJ, Yao, KJ, Liu, W, et al. Effects of anripsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry. 2004;184:58–62.CrossRefGoogle ScholarPubMed
101.Newcomer, J. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(suppl 1): 1–93.CrossRefGoogle ScholarPubMed
102.American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596–601.CrossRefGoogle Scholar
103.Simpson, GM, Glick, ID, Weiden, PJ, Romano, SJ, Siu, CO. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161:1837–1847.CrossRefGoogle ScholarPubMed
104.Simpson, GM, Weiden, P, Pigott, T, Murray, S, Siu, CO, Romano, SJ. Six-month, blinded, multicenter conrinuation study of ziprasidone versus olanzapine in schizophrenia. Am J Psychiatry. 2005;162:1535–1538.CrossRefGoogle ScholarPubMed
105.Sorensen, SV, Leaderer, MC, Harrison, DJ, et al. Psychiatric and metabolic outcomes of antipsychotics in schizophrenia. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2005; New Yotk, NY.Google Scholar
106.Marder, SR, McQuade, RD, Stock, E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res. 2003;61:123–136.CrossRefGoogle ScholarPubMed
107.Cheet, SM, Wagstaff, AJ. Quetiapine. A review of its use in the management of schizophrenia. CNS Drugs. 2004; 18(3): 173–199.Google Scholar
108.Fitzsimons, J, Berk, M, Lambert, T, Bourin, M, Dodd, S. A review of clozapine safety. Expert Opin Drug Saf. 2005;4(4):731–744.CrossRefGoogle ScholarPubMed
109.Pajonk, FG. Risperidone in acute and long-term rherapy of schizophrenia--a clinical profile. Prog Neuropsycbopharmacol Biol Psychiatry. 2004;28(1):15–23.CrossRefGoogle ScholarPubMed
110.Bhana, N, Foster, RH, Olney, R, Plosker, GL. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs. 2001;61(1):111–161.CrossRefGoogle ScholarPubMed
111.Moller, HJ. Risperidone: a review. Expert Opin Pharmacother. 2005;6(5):803–818.CrossRefGoogle ScholarPubMed
112.Swatnston Harrison, T, Perry, CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64(15):1715–1736.CrossRefGoogle Scholar
113. Clozaril (package insert). East Hanover, NJ: Novartis; January 2003.Google Scholar
114. Zyprexa (package insert). Indianapolis, IN: Eli Lilly; March 2004.Google Scholar
115. Abilify (package insert). Orsuka Pharmaceutical Co, Ltd (Tokyo) and Bristol-Myers Squibb (Princeton, NJ); March 2004.Google Scholar
116. Risperdal (package insert). Titusville, NJ: Janssen Pharmaceutical December 2003.Google Scholar
117. Seroquel (package insert). Wilmington, DE: AstraZeneca; January 2004.Google Scholar
118.Taylor, D. Ziprasidone in the management of schizophrenia: the QT interval issue in context. CNS Drugs. 2003;17:423–430.CrossRefGoogle Scholar
119.Montanez, A, Ruskin, JN, Hebert, PR, Lamas, GA, Hennekens, CH. Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population. Arch Int Med. 2004;164:943–948.CrossRefGoogle ScholarPubMed
120.Goldberg, RJ, Bengtson, J, Chen, ZY, Anderson, KM, Locati, E, Levy, D. Duration of the QT interval and total and cardiovascular mortality in healthy persons (The Framingham Heart Study experience). Am J Cardiol. 1991;67:55–58.CrossRefGoogle Scholar
121.Casey, DE, Haupt, DW, Newcomer, JW, et al. Antipsychotic-tnduced weight gain and metabolic abnormalities: Implications for increased mortality in patients with schizophrenia. J Clin Psychiatry. 2004;65(suppl 7):4–18.Google ScholarPubMed
122.Allison, DB, Mentore, JL, Heo, M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686–1696.CrossRefGoogle ScholarPubMed
123.Beasley, CM, Tollefson, GD, Tran, PV. Safety of olanzapine. J Clin Psychiatry. 1997;58:13–17.Google ScholarPubMed
124.Meyer, JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry. 2002;63:425–433.CrossRefGoogle ScholarPubMed
125.Wilson, PW, D'Agostino, RB, Levy, D, Belanget, AM, Silbershatz, H, Kannel, WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–1847.CrossRefGoogle ScholarPubMed
126.Wolf, PA, Abbott, RD, Kannet, WB. Atrial fibrillation as an independent risk factor for srroke: the Framingham Study. Stroke. 1991;22:983–988.CrossRefGoogle ScholarPubMed
127.Harrison, DJ, Leaderer, MC, Loebel, A, Murray, S. Ziprasidone, vs. olanzapine: change in CHD risk during a 6 week trial. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; Atlanta, GA.Google Scholar
128.Newcomet, J, Lebovitz, H. Course of weight and metabolic benefits one-year after switching to ziprasidone. Posrer presented at: 157th Annual Meeting of the American Psychiarric Associarion; May 1-6, 2004; Atlanta, GA.Google Scholar
129.Street, JS, Clark, WS, Gannon, KS, et al. Olanzapine tteatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry. 2000;57:968–976.CrossRefGoogle Scholar
130.De Deyn, PP, Carrasco, MM, Deberdt, W, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patienrs wirh Alzheimer's disease. Int J Geriatr Psychiatry. 2004;19:115–126.CrossRefGoogle ScholarPubMed
131.Wooltorton, E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ. 2002;167:1269–1270.Google ScholarPubMed
132. FDA Warning about Hyperglycemia and Atypical Anripsychotic Drugs, June 2004. Availableat: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/psn/printer. cfm?id=229. Accessed October 4, 2005.Google Scholar
133.Weiden, Pj, Mackell, J, Macdonell, D. Obesity as a risk factor for noncompliance. Schizophrenia Res. 2004;66:51–57.CrossRefGoogle ScholarPubMed